Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson Sells 7,779 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 7,779 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $16.29, for a total transaction of $126,719.91. Following the completion of the sale, the director now directly owns 447,857 shares in the company, valued at approximately $7,295,590.53. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Tyra Biosciences Stock Down 1.7 %

Shares of NASDAQ:TYRA opened at $15.91 on Wednesday. The stock has a market cap of $805.05 million, a price-to-earnings ratio of -9.88 and a beta of 1.04. The business’s 50 day moving average is $15.38 and its 200 day moving average is $19.20. Tyra Biosciences, Inc. has a 12-month low of $12.34 and a 12-month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, equities research analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, October 25th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, January 13th. UBS Group started coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price on the stock. Finally, Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Tyra Biosciences has an average rating of “Buy” and a consensus target price of $30.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. bought a new position in Tyra Biosciences during the third quarter valued at $278,000. Valence8 US LP bought a new position in shares of Tyra Biosciences during the 3rd quarter worth $310,000. SG Americas Securities LLC purchased a new stake in Tyra Biosciences in the 3rd quarter worth about $311,000. The Manufacturers Life Insurance Company bought a new stake in Tyra Biosciences in the 3rd quarter valued at about $333,000. Finally, HighVista Strategies LLC purchased a new stake in Tyra Biosciences during the second quarter valued at about $257,000. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.